688606 奥泰生物
已收盘 09-23 15:00:01
资讯
新帖
简况
每周股票复盘：奥泰生物（688606）中期拟每10股派10元
证券之星 · 09-20 20:32
每周股票复盘：奥泰生物（688606）中期拟每10股派10元
奥泰生物（688606）披露2025年中期利润分配方案，9月18日股价下跌1.45%
证券之星 · 09-18
奥泰生物（688606）披露2025年中期利润分配方案，9月18日股价下跌1.45%
奥泰生物(688606.SH)2025年中期利润分配拟10股派10元
智通财经 · 09-18
奥泰生物(688606.SH)2025年中期利润分配拟10股派10元
每周股票复盘：奥泰生物（688606）股东户数增8.08%，中报营收增8.41%
证券之星 · 08-31
每周股票复盘：奥泰生物（688606）股东户数增8.08%，中报营收增8.41%
奥泰生物（688606）2025年中报简析：营收净利润同比双双增长，三费占比上升明显
证券之星 · 08-30
奥泰生物（688606）2025年中报简析：营收净利润同比双双增长，三费占比上升明显
图解奥泰生物中报：第二季度单季净利润同比下降10.49%
证券之星 · 08-29
图解奥泰生物中报：第二季度单季净利润同比下降10.49%
医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道
国金证券 · 08-10
医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道
每周股票复盘：奥泰生物（688606）调整限制性股票授予价格并确定归属名单
证券之星 · 08-09
每周股票复盘：奥泰生物（688606）调整限制性股票授予价格并确定归属名单
奥泰生物：44万股限制性股票符合归属条件
财中社 · 08-08
奥泰生物：44万股限制性股票符合归属条件
奥泰生物：8月8日召开董事会会议
每日经济新闻 · 08-08
奥泰生物：8月8日召开董事会会议
单抗概念盘中跳水，康辰药业跌0.32%
市场透视 · 08-06
单抗概念盘中跳水，康辰药业跌0.32%
奥泰生物股价微跌0.01% 医疗器械企业成交额达7000万元
金融界 · 07-31
奥泰生物股价微跌0.01% 医疗器械企业成交额达7000万元
新冠抗原检测概念盘中跳水，奥泰生物跌0.28%
市场透视 · 07-29
新冠抗原检测概念盘中跳水，奥泰生物跌0.28%
世卫组织警示基孔肯雅热疫情风险，检测与驱蚊需求大涨，券商火线解读投资机会
每经网 · 07-27
世卫组织警示基孔肯雅热疫情风险，检测与驱蚊需求大涨，券商火线解读投资机会
奥泰生物获融资买入0.15亿元，近三日累计买入0.56亿元
金融界 · 07-26
奥泰生物获融资买入0.15亿元，近三日累计买入0.56亿元
基孔肯雅热国内情况点评：基孔肯雅热确诊病例快速上升 相关检测产品上市获批有望加速推进
光大证券 · 07-24
基孔肯雅热国内情况点评：基孔肯雅热确诊病例快速上升 相关检测产品上市获批有望加速推进
奥泰生物：包含针对基孔肯雅热等热带传染病的检测试剂
格隆汇资讯 · 07-23
奥泰生物：包含针对基孔肯雅热等热带传染病的检测试剂
奥泰生物获得实用新型专利授权：“一种用于便携式金标读数仪的可更换仓体”
证券之星企业动态 · 07-22
奥泰生物获得实用新型专利授权：“一种用于便携式金标读数仪的可更换仓体”
奥泰生物：公司在欧盟地区的销售主要以小额订单的体外快速诊断试剂为主
每日经济新闻 · 07-18
奥泰生物：公司在欧盟地区的销售主要以小额订单的体外快速诊断试剂为主
奥泰生物中标毛发尿检试剂项目 券商买入评级彰显增长潜力
自选股中标信息 · 07-18
奥泰生物中标毛发尿检试剂项目 券商买入评级彰显增长潜力
加载更多
公司概况
公司名称：
杭州奥泰生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2021-03-25
主营业务：
杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产和销售。公司的主要产品是传染病类、毒品及药物滥用类、妇女健康类、新冠检测类、肿瘤类、心肌类。报告期内，公司新增授权专利/软件著作权共23项；新增国内外医疗器械产品认证203项。截至报告期末，公司已累计获得专利/软件著作权219项，累计已取得国内外医疗器械备案以及产品注册证书3058项。
发行价格：
133.67
{"stockData":{"symbol":"688606","market":"SH","secType":"STK","nameCN":"奥泰生物","latestPrice":66.63,"timestamp":1758610801000,"preClose":67.71,"halted":0,"volume":498865,"delay":0,"changeRate":-0.016,"floatShares":79280900,"shares":79280900,"eps":3.9178,"marketStatus":"已收盘","change":-1.08,"latestTime":"09-23 15:00:01","open":67.51,"high":68.14,"low":65.96,"amount":33190900,"amplitude":0.0322,"askPrice":66.69,"askSize":36,"bidPrice":66.63,"bidSize":12,"shortable":0,"etf":0,"ttmEps":3.9178,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1758677400000},"marketStatusCode":5,"adr":0,"adjPreClose":67.71,"symbolType":"stock_kcb","openAndCloseTimeList":[[1758591000000,1758598200000],[1758603600000,1758610800000]],"highLimit":74.48,"lowLimit":60.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":79280855,"isCdr":false,"pbRate":1.35,"roa":"--","peRate":17.006994,"roe":"3.34%","epsLYR":3.82,"committee":-0.542373,"marketValue":5282000000,"turnoverRate":0.0063,"status":1,"afterMarket":{"amount":0,"volume":0,"close":66.63,"buyVolume":0,"sellVolume":286,"time":1758612839260,"indexStatus":"已收盘 09-23 15:30:00","preClose":67.71},"floatMarketCap":5282000000},"requestUrl":"/m/hq/s/688606","defaultTab":"news","newsList":[{"id":"2569246485","title":"每周股票复盘：奥泰生物（688606）中期拟每10股派10元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569246485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569246485?lang=zh_cn&edition=full","pubTime":"2025-09-21 04:32","pubTimestamp":1758400331,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，奥泰生物报收于68.4元，较上周的68.2元上涨0.29%。本周，奥泰生物9月19日盘中最高价报68.47元。本周关注点公司公告汇总：奥泰生物2025年中期拟每10股派发现金红利10元（含税）。致同会计师事务所已于2025年8月19日对公司激励对象出资情况进行审验，确认收到认缴股款10,357,453.01元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2568406204","title":"奥泰生物（688606）披露2025年中期利润分配方案，9月18日股价下跌1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568406204","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568406204?lang=zh_cn&edition=full","pubTime":"2025-09-18 23:01","pubTimestamp":1758207681,"startTime":"0","endTime":"0","summary":"截至2025年9月18日收盘，奥泰生物报收于67.09元，较前一交易日下跌1.45%，最新总市值为53.19亿元。该股当日开盘68.2元，最高68.28元，最低66.7元，成交额达4978.25万元，换手率为0.93%。近日，奥泰生物发布2025年中期利润分配方案公告。截至公告披露日，公司总股本为79,280,855股，扣减回购股份973,631股后，参与分配股数为78,307,224股，拟派发现金红利78,307,224.00元（含税）。本次利润分配方案已由第三届董事会第十六次会议和第三届监事会第十六次会议审议通过，无需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091800037929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2568422489","title":"奥泰生物(688606.SH)2025年中期利润分配拟10股派10元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568422489","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568422489?lang=zh_cn&edition=full","pubTime":"2025-09-18 16:24","pubTimestamp":1758183899,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥泰生物(688606.SH)公告，公司2025年中期利润分配方案拟每10股派发现金红利10元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2563835947","title":"每周股票复盘：奥泰生物（688606）股东户数增8.08%，中报营收增8.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563835947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563835947?lang=zh_cn&edition=full","pubTime":"2025-08-31 09:21","pubTimestamp":1756603271,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，奥泰生物报收于72.92元，较上周的75.29元下跌3.15%。本周，奥泰生物8月25日盘中最高价报76.8元。业绩披露要点：奥泰生物2025年中报显示，公司主营收入4.3亿元，同比上升8.41%；归母净利润1.32亿元，同比上升6.57%。公司公告汇总：2025年8月29日，奥泰生物向41名激励对象授予18.80万股限制性股票，授予价格调整为26.2993元/股。股本股东变化截至2025年6月30日，奥泰生物股东户数为5870户，较3月31日增加439户，增幅为8.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100002818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2563880448","title":"奥泰生物（688606）2025年中报简析：营收净利润同比双双增长，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2563880448","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563880448?lang=zh_cn&edition=full","pubTime":"2025-08-31 06:18","pubTimestamp":1756592337,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期奥泰生物发布2025年中报。截至本报告期末，公司营业总收入4.3亿元，同比上升8.41%，归母净利润1.32亿元，同比上升6.57%。本报告期奥泰生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达32.3%。然而去年的净利率为34.95%，算上全部成本后，公司产品或服务的附加值极高。持有奥泰生物最多的基金为鹏华弘嘉混合A，目前规模为4.52亿元，最新净值2.937，较上一交易日上涨0.77%，近一年上涨78.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100001690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2563704468","title":"图解奥泰生物中报：第二季度单季净利润同比下降10.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563704468","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563704468?lang=zh_cn&edition=full","pubTime":"2025-08-29 18:51","pubTimestamp":1756464709,"startTime":"0","endTime":"0","summary":"证券之星消息，奥泰生物2025年中报显示，公司主营收入4.3亿元，同比上升8.41%；归母净利润1.32亿元，同比上升6.57%；扣非净利润1.09亿元，同比上升17.27%；其中2025年第二季度，公司单季度主营收入2.21亿元，同比上升12.61%；单季度归母净利润7079.64万元，同比下降10.49%；单季度扣非净利润5108.74万元，同比下降8.02%；负债率5.93%，投资收益608.43万元，财务费用-1309.24万元，毛利率56.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900036704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2558835566","title":"医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道","url":"https://stock-news.laohu8.com/highlight/detail?id=2558835566","media":"国金证券","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558835566?lang=zh_cn&edition=full","pubTime":"2025-08-10 12:06","pubTimestamp":1754798792,"startTime":"0","endTime":"0","summary":"投资逻辑国内政策叠加资本双重支持，行业迎来重大发展机遇。近年来国内政策端对脑机接口行业支持力度较高，支持性政策在产品注册、医保支付、行业标准等层面均有体现。1）在产品注册方面，国家药监局将配合相关部门出台基于脑机接口技术的医疗器械产品支持政策，脑机接口相关产品有望通过创新器械绿色通道实现更快注册审批。其中医疗健康领域仍是脑机接口应用最大的细分领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081012063594da7295&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081012063594da7295&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603658","688607","688581","603014","688271","688273","688755","603880","688161","688338","688656","688050","688139","603222","688217","688212","688767","560260","600645","688410","688351","688575","688114","688193","688606","688389","688253","688016","600055","603387","688468","688108","688277","605369","688580","688366","603976","688236","688085","603205","688301","688314","688317","688677","688029","688393","688617","688151","600807","600587","688358","159883","688426","688013","688613","688067","688075","688026","688289","688298","603309","688576","688068","603987","600529","688198"],"gpt_icon":0},{"id":"2558500614","title":"每周股票复盘：奥泰生物（688606）调整限制性股票授予价格并确定归属名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2558500614","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558500614?lang=zh_cn&edition=full","pubTime":"2025-08-10 04:45","pubTimestamp":1754772311,"startTime":"0","endTime":"0","summary":"关于作废2022年限制性股票激励计划部分限制性股票的公告因3名激励对象离职，公司作废其已获授但尚未归属的限制性股票合计6,177股。关于2022年限制性股票激励计划首次授予第三个归属期及预留授予第二个归属期符合归属条件的公告首次授予第三个归属期拟归属409,472股，预留授予第二个归属期拟归属29,418股，合计438,890股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081000001046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2557528689","title":"奥泰生物：44万股限制性股票符合归属条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2557528689","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557528689?lang=zh_cn&edition=full","pubTime":"2025-08-08 17:12","pubTimestamp":1754644357,"startTime":"0","endTime":"0","summary":"8月8日，奥泰生物（688606）发布公告，公司2022年限制性股票激励计划首次授予第三个归属期及预留授予第二个归属期符合归属条件。本次可归属的限制性股票数量合计为44万股，本次首次授予符合条件的94名激励对象可归属的限制性股票数量合计为41万股，预留授予符合条件的18名激励对象可归属的限制性股票数量合计为3万股。2025年一季度，奥泰生物实现收入2.08亿元，归母净利润6122万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080817355194d76ca5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080817355194d76ca5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2557864522","title":"奥泰生物：8月8日召开董事会会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2557864522","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557864522?lang=zh_cn&edition=full","pubTime":"2025-08-08 17:10","pubTimestamp":1754644235,"startTime":"0","endTime":"0","summary":"每经AI快讯，奥泰生物（SH 688606，收盘价：74.15元）8月8日晚间发布公告称，公司第三届第十四次董事会会议于2025年8月8日在公司会议室以现场与通讯相结合的方式召开。会议审议了《关于<调整2022年限制性股票激励计划授予价格>的议案》等文件。2024年1至12月份，奥泰生物的营业收入构成为：体外诊断行业占比99.51%，其他业务占比0.49%。截至发稿，奥泰生物市值为59亿元。每经头条（nbdtoutiao）——时速21万公里，外星探测器伪装成彗星将“攻击”地球？哈佛知名教授：建议全球建立“宇宙防御系统”！中国专家：并无明显异常（记者 曾健辉）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808173525973b81a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808173525973b81a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2557347151","title":"单抗概念盘中跳水，康辰药业跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557347151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557347151?lang=zh_cn&edition=full","pubTime":"2025-08-06 13:01","pubTimestamp":1754456516,"startTime":"0","endTime":"0","summary":"08月06日，单抗概念盘中跳水，截至13点01分，单抗概念整体指数下跌1.01%，报2737.040点。从个股上来看，该概念的成分股中，康辰药业跌0.32%，迈威生物-U、奥泰生物跌幅居前。从资金上来看，截止发稿，单抗概念概念主力净流入为-10.46亿，其中康弘药业受到资金热捧，主力净流入2344.43万；拉长时间线来看，该板块近20日主力资金净流入-21.23亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080613015694d2b847&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080613015694d2b847&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","603590","BK0239","688606"],"gpt_icon":0},{"id":"2556832952","title":"奥泰生物股价微跌0.01% 医疗器械企业成交额达7000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556832952","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556832952?lang=zh_cn&edition=full","pubTime":"2025-07-31 23:47","pubTimestamp":1753976852,"startTime":"0","endTime":"0","summary":"截至2025年7月31日收盘，奥泰生物股价报71.72元，较前一交易日微跌0.01%。当日成交量为9660手，成交金额达到7000万元，振幅为3.12%。奥泰生物是一家专注于体外诊断试剂研发、生产和销售的高新技术企业，主要产品包括传染病检测、毒品检测、肿瘤标志物检测等系列试剂。公司所属医疗器械行业，涉及痘病毒防治、单抗概念等细分领域。从资金流向来看，7月31日主力资金净流出509.79万元，占流通市值的0.09%。风险提示：股市有风险，投资需谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/31234752120421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09997","BK1574","09996","BK1222","BK0239","BK1583","688606","BK1100","159883"],"gpt_icon":0},{"id":"2555108598","title":"新冠抗原检测概念盘中跳水，奥泰生物跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555108598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555108598?lang=zh_cn&edition=full","pubTime":"2025-07-29 09:50","pubTimestamp":1753753808,"startTime":"0","endTime":"0","summary":"07月29日，新冠抗原检测概念盘中跳水，截至09点50分，新冠抗原检测概念整体指数下跌1.01%，报1042.120点。从个股上来看，该概念的成分股中，奥泰生物跌0.28%，跌幅居前。从资金上来看，截止发稿，新冠抗原检测概念主力净流入为-4.03亿，其中翰宇药业受到资金热捧，主力净流入2809.74万；拉长时间线来看，该板块近20日主力资金净流入-40.45亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072909500897244abf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072909500897244abf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2554723717","title":"世卫组织警示基孔肯雅热疫情风险，检测与驱蚊需求大涨，券商火线解读投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2554723717","media":"每经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554723717?lang=zh_cn&edition=full","pubTime":"2025-07-27 14:40","pubTimestamp":1753598442,"startTime":"0","endTime":"0","summary":"近期，基孔肯雅热疫情在广东部分地区传播引发关注。尽管卖方对基孔肯雅热相关主题关注度较低，缺乏相关研报，但检测领域受到关注，A股多家企业已有检测解决方案。世界卫生组织7月25日警告，基孔肯雅热病毒正在全球多地扩散，已有119个国家报告病例，约550万人面临感染风险。目前，此次疫情的传播也逐渐被资本市场所关注。另据多家媒体报道，当前防控基孔肯雅热疫情，防蚊、灭蚊是关键。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072714443294bd3079&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072714443294bd3079&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688767","688193","603193","688317","688399","600486","688606","BK0239","159982","688289","399300"],"gpt_icon":0},{"id":"2554079708","title":"奥泰生物获融资买入0.15亿元，近三日累计买入0.56亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554079708","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554079708?lang=zh_cn&edition=full","pubTime":"2025-07-26 08:02","pubTimestamp":1753488157,"startTime":"0","endTime":"0","summary":"7月25日，沪深两融数据显示，奥泰生物获融资买入额0.15亿元，居两市第1059位，当日融资偿还额0.17亿元，净卖出201.80万元。最近三个交易日，23日-25日，奥泰生物分别获融资买入0.16亿元、0.24亿元、0.15亿元。融券方面，当日融券卖出0.00万股，净卖出0.00万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726081544971f58f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726081544971f58f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2554759750","title":"基孔肯雅热国内情况点评：基孔肯雅热确诊病例快速上升 相关检测产品上市获批有望加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2554759750","media":"光大证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554759750?lang=zh_cn&edition=full","pubTime":"2025-07-25 00:00","pubTimestamp":1753372800,"startTime":"0","endTime":"0","summary":"事件：2025 年7 月，基孔肯雅热在国内外引发广泛关注。截至7 月23 日，佛山全市已累计公开报告基孔肯雅热确诊病例3645 例。核酸检测和病毒分离鉴定阳性后，可确诊基孔肯雅热病毒感染。此轮对于基孔肯雅热病例检测有望推动相关检测产品快速积累临床数据，加速推动产品上市获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725144620a6c11245&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725144620a6c11245&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688317","688606","688193","688399","688289"],"gpt_icon":0},{"id":"2553218596","title":"奥泰生物：包含针对基孔肯雅热等热带传染病的检测试剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2553218596","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553218596?lang=zh_cn&edition=full","pubTime":"2025-07-23 16:26","pubTimestamp":1753259176,"startTime":"0","endTime":"0","summary":"格隆汇7月23日丨奥泰生物(688606.SH)在互动平台表示，公司传染病检测系列产品覆盖广泛，包含针对基孔肯雅热等热带传染病的检测试剂。目前该产品仅面向境外市场进行销售。如需在国内市场进行销售，需要取得相应的国内医疗器械注册证书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723162645954e59e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723162645954e59e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2553059268","title":"奥泰生物获得实用新型专利授权：“一种用于便携式金标读数仪的可更换仓体”","url":"https://stock-news.laohu8.com/highlight/detail?id=2553059268","media":"证券之星企业动态","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553059268?lang=zh_cn&edition=full","pubTime":"2025-07-23 02:56","pubTimestamp":1753210601,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示奥泰生物新获得一项实用新型专利授权，专利名为“一种用于便携式金标读数仪的可更换仓体”，专利申请号为CN202421902553.1，授权日为2025年7月8日。今年以来奥泰生物新获得专利授权20个，较去年同期增加了66.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072303014497b10e4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072303014497b10e4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2552449803","title":"奥泰生物：公司在欧盟地区的销售主要以小额订单的体外快速诊断试剂为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2552449803","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552449803?lang=zh_cn&edition=full","pubTime":"2025-07-18 21:24","pubTimestamp":1752845073,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问贵公司在欧盟的销售以中小额订单和民营医疗机构为主吗？奥泰生物（688606.SH）7月18日在投资者互动平台表示，公司专注于体外诊断行业中的POCT细分领域，主营业务为体外快速诊断试剂的研发、生产和销售，主要产品为体外快速诊断试剂。公司在欧盟地区的销售主要以小额订单的体外快速诊断试剂为主。（记者 毕陆名）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071821250397ab2f00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071821250397ab2f00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2552467394","title":"奥泰生物中标毛发尿检试剂项目 券商买入评级彰显增长潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2552467394","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552467394?lang=zh_cn&edition=full","pubTime":"2025-07-18 18:57","pubTimestamp":1752836252,"startTime":"0","endTime":"0","summary":"2025年07月18日，据天眼查数据，浙江豪圣建设项目管理有限公司关于杭州市公安局滨江区分局毛发检测试剂、尿检检测试剂采购项目中标(成交)结果公告显示，中标方为奥泰生物，招标方为杭州市公安局滨江区分局。近半年内，奥泰生物获得2家券商积极评价：开源证券和东吴证券给予\"买入\"评级。奥泰生物主营业务涵盖传染病类，毒品及药物滥用类，其他类，其他收入之和。截至发稿，奥泰生物股价报68.25元，上涨0.41%，成交额至3637.59万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718185737a4535d23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718185737a4535d23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1758618993006,"stockEarnings":[{"period":"1week","weight":-0.0001},{"period":"1month","weight":-0.1007},{"period":"3month","weight":0.0396},{"period":"6month","weight":-0.0386},{"period":"1year","weight":0.261},{"period":"ytd","weight":0.0932}],"compareEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.1193},{"period":"6month","weight":0.1365},{"period":"1year","weight":0.3989},{"period":"ytd","weight":0.1423}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州奥泰生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5870人(较上一季度增加8.08%)","perCapita":"13506股","listingDate":"2021-03-25","address":"浙江省杭州市钱塘区经济技术开发区白杨街道银海街550号第3幢第4幢第5幢厂房","registeredCapital":"7928万元","survey":" 杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产和销售。公司的主要产品是传染病类、毒品及药物滥用类、妇女健康类、新冠检测类、肿瘤类、心肌类。报告期内，公司新增授权专利/软件著作权共23项；新增国内外医疗器械产品认证203项。截至报告期末，公司已累计获得专利/软件著作权219项，累计已取得国内外医疗器械备案以及产品注册证书3058项。","listedPrice":133.67},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥泰生物,688606,奥泰生物股票,奥泰生物股票老虎,奥泰生物股票老虎国际,奥泰生物行情,奥泰生物股票行情,奥泰生物股价,奥泰生物股市,奥泰生物股票价格,奥泰生物股票交易,奥泰生物股票购买,奥泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}